Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VISHAL K BHAGAT

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1649364381
CMS profile
119707
Location
ROANOKE, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,991.66

73 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,991.66 73

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 73 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VISHAL K BHAGAT

NPI 1649364381 · CMS profile ID 119707

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

ROANOKE, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 73 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1649364381?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VISHAL K BHAGAT, NPI 1649364381, CMS profile ID 119707. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 73 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649364381?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). VISHAL K BHAGAT, NPI 1649364381, CMS profile ID 119707. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 73 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649364381?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
VISHAL K BHAGAT, NPI 1649364381, CMS profile ID 119707, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 73 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1649364381?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

73 matching records · $1,991.66 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 73 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 73.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $17.1312/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201512038 CMS
ABBVIE INC. $20.3912/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201512036 CMS
Regeneron Healthcare Solutions, Inc. $26.2412/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212873969 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.3812/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223860562 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $19.8011/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232018624 CMS
ABBVIE INC. $13.7711/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201512032 CMS
ABBVIE INC. $1.0211/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201512034 CMS
Aimmune Therapeutics, Inc. $17.1011/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249701999 CMS
PFIZER INC. $29.9011/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229397793 CMS
Novo Nordisk Inc $110.2311/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188890054 CMS
PFIZER INC. $20.6111/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230021489 CMS
QOL Medical, LLC $18.1510/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1185027214 CMS
ABBVIE INC. $23.5210/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201512030 CMS
Novo Nordisk Inc $21.8810/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188973897 CMS
ABBVIE INC. $18.7610/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201512028 CMS
Ipsen Biopharmaceuticals, Inc $20.8910/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208831897 CMS
Janssen Biotech, Inc. $21.3610/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175276085 CMS
ABBVIE INC. $15.3309/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201512026 CMS
Ardelyx, Inc. $16.4609/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247835526 CMS
Janssen Biotech, Inc. $25.0009/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175276595 CMS
ABBVIE INC. $1.0009/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201512022 CMS
ABBVIE INC. $12.3209/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201512024 CMS
Aimmune Therapeutics, Inc. $13.6109/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249701993 CMS
ABBVIE INC. $20.5509/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201512020 CMS
Intercept Pharmaceuticals, Inc. $13.5308/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249878410 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.1908/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223858965 CMS
ABBVIE INC. $15.7908/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201512018 CMS
ABBVIE INC. $0.3108/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201512014 CMS
ABBVIE INC. $16.8108/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201512016 CMS
Celltrion USA Inc. $20.9907/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250818903 CMS
Janssen Biotech, Inc. $21.5907/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175275522 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $117.5207/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232018622 CMS
Madrigal Pharmaceuticals $44.2207/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248236232 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.3107/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232018620 CMS
Madrigal Pharmaceuticals $2.5807/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248236230 CMS
Phathom Pharmaceuticals, Inc. $20.7107/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219250001 CMS
Regeneron Healthcare Solutions, Inc. $24.7006/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212873967 CMS
Janssen Biotech, Inc. $5.6406/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175276997 CMS
Janssen Biotech, Inc. $10.3006/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175275795 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $21.6106/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232018626 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $112.3106/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232018618 CMS
Gilead Sciences, Inc. $26.5405/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234461724 CMS
Regeneron Healthcare Solutions, Inc. $22.8405/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212873965 CMS
Janssen Scientific Affairs, LLC $99.8205/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174202121 CMS
Janssen Biotech, Inc. $8.0305/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175277097 CMS
Aimmune Therapeutics, Inc. $16.1605/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249701997 CMS
ABBVIE INC. $26.2605/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201512012 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.9005/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232018616 CMS
Janssen Biotech, Inc. $96.1904/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175275725 CMS
Gilead Sciences, Inc. $24.8504/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234476140 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $509.08 7
PY2020 $4,938.68 11
PY2021 $32.27 1
PY2022 $75.82 5
PY2023 $919.12 40
PY2024 $2,031.07 67
PY2025 $1,991.66 73

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,849.40 2
PY2025 Principal investigator $55,610.00 40
PY2024 Principal investigator $62,278.00 40
PY2023 Principal investigator $8,000.00 1
PY2021 Principal investigator $102,250.00 536
PY2020 Principal investigator $199,035.36 32
PY2019 Principal investigator $310,985.31 63

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $34,607.36 12/31/2020 Non-covered Recipient Entity
PARAGON INTERNATIONAL INC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721317343
Principal investigator 1 Allergan, Inc. $385.00 12/15/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721311989
Principal investigator 1 Allergan, Inc. $600.00 12/03/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721310819
Principal investigator 1 Allergan, Inc. $45.00 12/03/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721310827
Principal investigator 1 Allergan, Inc. $4,778.50 11/16/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721308253
Principal investigator 1 Allergan, Inc. $225.00 11/01/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721305943
Principal investigator 1 Allergan, Inc. $115.00 10/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721304947
Principal investigator 1 Allergan, Inc. $9,000.00 10/19/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 721303573
Principal investigator 1 Allergan, Inc. $9,875.25 10/19/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721303767
Principal investigator 1 Allergan, Inc. $247.50 10/09/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721302049
Principal investigator 1 Allergan, Inc. $115.00 10/06/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721301669
Principal investigator 1 Allergan, Inc. $3,087.50 09/18/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721298713
Principal investigator 1 Allergan, Inc. $35,905.25 08/19/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721291297
Principal investigator 1 Allergan, Inc. $115.00 08/12/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721289791
Principal investigator 1 Allergan, Inc. $45.00 08/12/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721289793
Principal investigator 1 Allergan, Inc. $700.00 08/11/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721289547
Principal investigator 1 Allergan, Inc. $540.00 08/11/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721289549
Principal investigator 1 Allergan, Inc. $180.00 08/11/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721289555
Principal investigator 1 Allergan, Inc. $900.00 08/07/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721288933
Principal investigator 1 Allergan, Inc. $360.00 08/07/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721288939
Principal investigator 1 Allergan, Inc. $180.00 08/07/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721288943
Principal investigator 1 Allergan, Inc. $115.00 08/07/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721288947
Principal investigator 1 Allergan, Inc. $75.00 08/07/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721288951
Principal investigator 1 Allergan, Inc. $15,333.00 07/20/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721285429
Principal investigator 1 Allergan, Inc. $10,013.25 05/25/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721276871
Principal investigator 1 Allergan, Inc. $20,477.25 04/20/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721271369
Principal investigator 1 Allergan, Inc. $345.00 04/01/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721268431
Principal investigator 1 Allergan, Inc. $325.00 04/01/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721268435
Principal investigator 1 Allergan, Inc. $12,169.50 03/18/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721265717
Principal investigator 1 Allergan, Inc. $955.00 03/10/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721262739
Principal investigator 1 Allergan, Inc. $32,418.75 02/17/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721257907
Principal investigator 1 Allergan, Inc. $4,802.25 01/20/2020 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721248795